Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9058756 | 0.82 | ALDH1A1 (0.44) | EGLN1ALDH1A1NPSR1KMT2AMAPT | |
| SCHEMBL1723694 | 0.82 | MAPT (0.42) | EGLN1ALDH1A1NPSR1KMT2AMAPT | |
| SCHEMBL6410089 | 0.80 | FAAH (0.51) | FAAHTSHR | |
| SCHEMBL87647 | 0.79 | — | — | |
| Methyl Alcohol SCHEMBL11130161 | 0.78 | ALDH1A1 (0.46) | ALDH1A1NPSR1KMT2AMAPTFAAH | |
| SCHEMBL923438 | 0.76 | EGLN1 (0.65) | EGLN1ALDH1A1NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL12495312 | 0.76 | EGLN1 (0.65) | EGLN1ALDH1A1NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL13589411 | 0.76 | EGLN1 (0.65) | EGLN1ALDH1A1NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL21446034 | 0.76 | KMT2A (0.39) | ALDH1A1KMT2AMAPTFAAHSMN1; SMN2 | |
| SCHEMBL4952777 | 0.75 | TSHR (0.56) | ALDH1A1KMT2AMAPTFAAHSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-110914273-B | [1,2,4] triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | 伊莱利利公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2022227015-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232333-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
| US-11401274-B2 | [1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | ELI LILLY AND COMPANY (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3665174-B1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | LILLY CO ELI (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3665174-B1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | LILLY CO ELI (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-3414249-B1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210147437-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY | 2021-05-20 | — | — | US | disclosed |
| US-20180099973-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2018-04-12 | — | — | US | disclosed |
| US-9868741-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868741-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868741-B2 | PDE1 inhibitor | ELI LILLY AND COMPANY (US) | 2018-01-16 | — | — | US | disclosed |
| WO-2017139186-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139186-A1 | PDE1 INHIBITOR | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | WO | disclosed |
| US-20170233396-A1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233396-A1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233396-A1 | PDE1 INHIBITOR | LILLY CO ELI (US) | 2017-08-17 | — | — | US | disclosed |
| US-5021081-A | Herbicidal substituted triazoles | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147437-A1 | [1,2,4]TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES | PDE3B, PDE3A, PDE5A | EGLN1 1240/4885ALDH1A1 1586/4885NPSR1 2015/4885 |
| US-11401274-B2 | [1,2,4]Triazolo derivatives as PDE1 inhibitors for the treatment of diabetes | PDE3B, PDE3A, PDE5A | EGLN1 1240/4885ALDH1A1 1586/4885NPSR1 2015/4885 |
| US-20180099973-A1 | PDE1 INHIBITOR | PDE3B, PDE5A, PDE3A | EGLN1 239/4885ALDH1A1 101/4885NPSR1 2093/4885 |
| US-20170233396-A1 | PDE1 INHIBITOR | PDE3B, PDE5A, PDE3A | EGLN1 239/4885ALDH1A1 101/4885NPSR1 2093/4885 |
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | EGLN1 955/4885ALDH1A1 283/4885NPSR1 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.